Literature DB >> 19395195

Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation.

Jaroslaw T Hepel1, Mari Tokita, Stephanie G MacAusland, Suzanne B Evans, Jessica R Hiatt, Lori Lyn Price, Thomas DiPetrillo, David E Wazer.   

Abstract

PURPOSE: To assess the incidence and severity of late normal tissue toxicity using three-dimensional conformal radiotherapy to deliver accelerated partial breast irradiation. METHODS AND MATERIALS: A total of 60 patients were treated with three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Treatment planning and delivery were in strict accordance with the technique and specified dose-volume constraints of the National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group 0413 protocol. Late toxicity was evaluated according to the Radiation Therapy Oncology Group grading schema. The cosmetic outcome was scored using the Harvard criteria. Univariate logistic regression analysis was performed to evaluate the correlation of dosimetric variables with outcome.
RESULTS: At a median follow-up of 15 months, moderate-to-severe late toxicity developed in 10% of patients. The most pronounced late toxicity was subcutaneous fibrosis: 25% Grade 2-4 and 8.3% Grade 3-4. The modified planning tumor volume/whole breast volume ratio, ratio of the volume of breast tissue receiving 5%, 20%, 50%, and 80% of the prescription dose to the whole breast volume, and maximal dose within the breast correlated with the development of fibrosis (p = .10, p = .03, p = .04, p = .06, p = .09, and p = .046, respectively). The overall cosmetic outcome was good to excellent in 81.7%, fair in 11.7%, and poor in 6.7%. The presence of subcutaneous fibrosis, modified planning tumor volume/whole breast volume ratio, ratio of the volume of breast tissue receiving 5% and 20% of the prescription dose to the whole breast volume, and pathologic specimen volume correlated with the risk of a fair/poor cosmetic outcome (p < .001, p = .02, p = .05, p = .04, p = .01, respectively).
CONCLUSION: The three-dimensional conformal radiotherapy technique for accelerated partial breast irradiation as specified in the National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group 0413 protocol resulted in a remarkably high rate of moderate-to-severe late normal tissue effects, despite the relatively brief follow-up period. The toxic events correlated clearly with several dose-volume parameters.

Entities:  

Mesh:

Year:  2009        PMID: 19395195     DOI: 10.1016/j.ijrobp.2009.01.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  50 in total

1.  Analysis of fat necrosis after adjuvant high-dose-rate interstitial brachytherapy for early stage breast cancer.

Authors:  Adam A Garsa; Daniel J Ferraro; Todd Dewees; Julie A Margenthaler; Michael Naughton; Rebecca Aft; William E Gillanders; Timothy Eberlein; Melissa A Matesa; Imran Zoberi
Journal:  Brachytherapy       Date:  2012-06-20       Impact factor: 2.362

2.  [Risks of unfavorable cosmetic and toxicity after percutaneous accelerated partial breast irradiation (APBI). Interim analysis from the Canadian RAPID trial].

Authors:  M D Piroth
Journal:  Strahlenther Onkol       Date:  2013-12       Impact factor: 3.621

3.  [Arrhythmias].

Authors:  Lars Eckardt
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-11       Impact factor: 0.840

4.  GammaPod-a new device dedicated for stereotactic radiotherapy of breast cancer.

Authors:  Cedric X Yu; Xinyu Shao; Jin Zhang; William Regine; Mike Zheng; Ying S Yu; Jianchun Deng; Zhengcheng Duan
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

5.  Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience.

Authors:  L E Henke; J A Contreras; O L Green; B Cai; H Kim; M C Roach; J R Olsen; B Fischer-Valuck; D F Mullen; R Kashani; M A Thomas; J Huang; I Zoberi; D Yang; V Rodriguez; J D Bradley; C G Robinson; P Parikh; S Mutic; J Michalski
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-09-07       Impact factor: 4.126

Review 6.  Recent developments and best practice in brachytherapy treatment planning.

Authors:  C D Lee
Journal:  Br J Radiol       Date:  2014-06-02       Impact factor: 3.039

7.  Implementation of image-guided intensity-modulated accelerated partial breast irradiation : Three-year results of a phase II clinical study.

Authors:  Norbert Mészáros; Tibor Major; Gábor Stelczer; Zoltán Zaka; Emőke Mózsa; Dávid Pukancsik; Zoltán Takácsi-Nagy; János Fodor; Csaba Polgár
Journal:  Strahlenther Onkol       Date:  2016-11-21       Impact factor: 3.621

8.  First experience of carbon-ion radiotherapy for early breast cancer.

Authors:  Hiroko Akamatsu; Kumiko Karasawa; Tokuhiko Omatsu; Yoshiharu Isobe; Risa Ogata; Yusuke Koba
Journal:  Jpn J Radiol       Date:  2014-03-11       Impact factor: 2.374

9.  Decline of cosmetic outcomes following accelerated partial breast irradiation using intensity modulated radiation therapy: results of a single-institution prospective clinical trial.

Authors:  Adam L Liss; Merav A Ben-David; Reshma Jagsi; James A Hayman; Kent A Griffith; Jean M Moran; Robin B Marsh; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-07       Impact factor: 7.038

Review 10.  Accelerated Partial Breast Irradiation (APBI): A review of available techniques.

Authors:  Christopher F Njeh; Mark W Saunders; Christian M Langton
Journal:  Radiat Oncol       Date:  2010-10-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.